News
TNDM
42.75
+0.31%
0.13
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 49% Undervaluation?
In this article we are going to estimate the intrinsic value of Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) by...
Simply Wall St. · 11/24 12:28
Tandem Diabetes Care Earns Great Place to Work Certification™
SAN DIEGO, November 16, 2022--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, is proud to announce its Great Place to Work Certification™, a prestigious award based entirely on results from in-depth empl...
Business Wire · 11/16 21:05
Tandem upgraded at Wells Fargo as valuation and consensus reset
Seekingalpha · 11/15 13:25
Wells Fargo Upgrades Tandem Diabetes Care to Equal-Weight, Announces $43 Price Target
Benzinga · 11/15 11:30
BRIEF-Tandem Diabetes Care Study Demonstrates Improvements Of All Clinical Endpoints In Adults With Type 2 Diabetes Using Control-IQ Technology
Reuters · 11/10 22:52
Tandem Diabetes Care Study Demonstrates Improvements Of All Clinical Endpoints In Adults With Type 2 Diabetes Using Control-IQ Technology
Benzinga · 11/10 22:23
Tandem Diabetes Care Announces Upcoming Conference Presentation
SAN DIEGO, November 08, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wed...
Business Wire · 11/08 21:05
--Raymond James Adjusts Price Target on Tandem Diabetes Care to $52 From $92, Maintains Outperform Rating
--Raymond James Adjusts Price Target on Tandem Diabetes Care to $52 From $92, Maintains Outperform Rating
MT Newswires · 11/04 13:10
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
Benzinga · 11/04 10:06
Raymond James Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $52
Benzinga · 11/04 09:25
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Benzinga · 11/04 08:41
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 11/03 18:35
HUDI and VAPO among mid-day movers
Seekingalpha · 11/03 17:06
Virax, Veracyte top healthcare gainers; Vapotherm, Aurinia lead losers' pack
Seekingalpha · 11/03 14:00
QUALCOMM, Nutrien, Moderna among premarket losers' pack
Seekingalpha · 11/03 13:08
Tandem Diabetes Shares Slump After Dismal Annual Outlook
Benzinga · 11/03 12:22
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/03 12:22
--Lake Street Adjusts Price Target on Tandem Diabetes Care to $60 From $150, Maintains Buy Rating
--Lake Street Adjusts Price Target on Tandem Diabetes Care to $60 From $150, Maintains Buy Rating
MT Newswires · 11/03 11:43
Piper Sandler Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $70
Benzinga · 11/03 10:43
Research Alert: CFRA Maintains Buy Opinion On Shares Of Tandem Diabetes Care
Research Alert: CFRA Maintains Buy Opinion On Shares Of Tandem Diabetes Care
MT Newswires · 11/03 10:01
More
Webull provides a variety of real-time TNDM stock news. You can receive the latest news about Tandem Diabetes through multiple platforms. This information may help you make smarter investment decisions.
About TNDM
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The Company's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.